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Polydeoxyribonucleotide (PDRN) restores blood
flow in an experimental model of peripheral artery
occlusive disease
Alessandra Bitto, MD,a Francesca Polito, PhD,a Domenica Altavilla, PhD,a Letteria Minutoli, MD,a
Alba Migliorato, PhD,b and Francesco Squadrito, MD,a Messina, Italy
Objective: This study investigated whether polydeoxyribonucleotide (PDRN) may be efficacious in the treatment of
peripheral artery occlusive diseases, which are a major cause of morbidity in Western countries and still lack standardized
treatment.
Methods:We investigated the effects of PDRN, a mixture of deoxyribonucleotides, in an experimental model of hind limb
ischemia (HLI) in rats to stimulate vascular endothelial growth factor (VEGF)-A production and to avoid critical
ischemia. The femoral artery was excised to induce HLI. Sham-operated on rats (sham HLI) were used as controls.
Animals were treated daily with intraperitoneal PDRN (8 mg/kg) or its vehicle. Animals were euthanized at day 7, 14,
and 21 after the evaluation of blood flow by laser Doppler. Dissected muscles were used to measure VEGF-A messenger
RNA (mRNA) and protein expression, to evaluate edema, and to assess histologic damage.
Results: Administration of PDRN dramatically increased VEGF mRNA throughout the study (day 14: HLI, 7  2.2
n-fold/-actin; HLI PDRN, 13.3 3.8 n-fold/-actin; P< .0001) and protein expression (HLI, 11 3.4 integrated
intensity; HLI  PDRN, 16  3.8 integrated intensity; P < .0001). The compound stimulated revascularization, as
confirmed by blood flow restoration (P < .005 vs HLI  vehicle), and blunted the histologic damage and the degree of
edema. PDRN did not modify VEGF-A expression and blood flow in sham HLI animals. Furthermore, the concomitant
administration of 3,7-dimethyl-1-propargilxanthine (DMPX), a selective adenosine A2A receptor antagonist, abolished
the positive effects of PDRN, confirming that PDRN acts through this receptor.
Conclusion: These results led us to hypothesize a role for PDRN in treating peripheral artery occlusive diseases. ( J Vasc
Surg 2008;48:1292-1300.)
Clinical Relevance: The compound polydeoxyribonucleotide (PDRN), acting through the adenosine receptors, which are
expressed during ischemia, can stimulate therapeutic angiogenesis during ischemic conditions without any adverse effect.
Owing to this peculiar frame of activity, its use is also safe in diabetic patients where an augmented vascular endothelial
growth factor production can be disadvantageous, as we have already demonstrated.Peripheral arterial occlusive disease (PAOD) of the
lower extremities is becoming more prevalent worldwide.
The general prognosis for patients with peripheral arterial
disease is particularly negative; in fact, such patients have a
high prevalence of coronary heart disease and cerebrovas-
cular disease.1 Nonsurgical treatment options provide the
foundation for management; in this effort, several thera-
peutic agents have been used with success and others are
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1292still undergoing testing. Definitive recommendations can-
not be made on the use of specific drugs until further
evaluation is completed.2,3
Ongoing research with new strategies for angiogenesis
and the use of progenitor cells has yielded encouraging
results, particularly for patients with critical limb ischemia
and limited options.4,5 The most effective angiogenic mol-
ecule is vascular endothelial growth factor (VEGF), and
especially the isoform 165 of VEGF-A (hereinafter VEGF),
which is able to stimulate new vessels formation also during
adult life. Different cell types release VEGF in response to
an ischemic injury, and it is of crucial importance to direct
angiogenesis towards nonperfused tissue.
To study the possible beneficial effects of therapies,
several animal models have been described in recent years;
however, ligation and excision of the animal’s left femoral
artery, which results in a significant decrease of blood flow
in the ischemic limb, has been recognized one of the most
JOURNAL OF VASCULAR SURGERY
Volume 48, Number 5 Bitto et al 1293effective to reproduce PAOD.6 Furthermore, these exper-
imental conditions make it possible to assess the hypoxia-
driven angiogenic response and to determine the residual
perfusion by laser Doppler analysis.7
An increase in VEGF has been shown as a result of
adenosine A2A receptor stimulation. This seems to be me-
diated directly by increasing endothelial cell migration and
microvascular endothelial cell VEGF production8,9 and
also indirectly through promotion of VEGF production by
macrophages.10
Polydeoxyribonucleotide (PDRN) is a compound that,
acting through adenosine receptors, is able to stimulate
VEGF production during pathologic conditions of low
tissue perfusion such as diabetes mellitus and thermal
injury.11,12 PDRN is the active fraction of a preparation
used in therapy as an agent to stimulate tissue repair and is
extracted from the sperm of trout bred for human con-
sumption. The drug is obtained by an extraction process
with purifying and high temperature sterilizing procedures
to obtain an 95% pure active principle without pharma-
cologically active proteins and peptides (Registration Dos-
sier, Italian Ministry of Health).13 This compound holds a
mixture of deoxyribonucleotides polymers with chain lengths
ranging between 50 and 2000 bp and may also represent
the source of purine and pyrimidine deoxynucleosides/
deoxyribonucleotides and bases.
The aim of our work was to study the possible beneficial
role of PDRN in a rat model of hind limb ischemia (HLI).
More in detail, we investigated the angiogenic process
through VEGF expression and laser Doppler evaluation.
MATERIALS AND METHODS
This investigation conforms with theGuide for the Care
and Use of Laboratory Animals (National Institutes of
Health Publication No. 85-23, revised 1996).
Animals. The study used male Sprague-Dawley rats
(250 to 300 g) fed on a standard diet and with tap water ad
libitum and kept in a 12-hour light-dark cycle. The tem-
perature of the animals was maintained at approximately
37°C using an overhead lamp during the experiment. En-
vironmental conditions (light, temperature and humidity)
have been constantly maintained in the vivarium for all the
time of the experiment and especially during laser Doppler
evaluations.
Experimental procedures. The surgical procedures
have been performed as previously described.14 Briefly, rats
were anesthetized with an intraperitoneal (IP) injection of
sodium pentobarbital (50mg/kg). Hair was removed from
the hindquarters with a depilating cream, with care taken to
avoid erythema. The left femoral artery was exposed asep-
tically through a 2-mm incision and isolated from the
femoral vein and nerve, with care taken to avoid damage to
vessels or nerve, then was ligated with 7-0 suture just distal
to the bifurcation of the anterior epigastric and lateral
caudal femoral arteries. Finally, the femoral artery was
excised from the ligation to the point distally where it
bifurcates into the saphenous and popliteal arteries. As a
consequence, blood flow to the ischemic limb becomescompletely dependent on the collateral vessels (HLI ani-
mals). Control animals underwent sham operations (sham
HLI) that consisted of all surgical procedures except for
artery ligation and consequent excision.
Animals were randomized to receive daily IP PDRN or
its vehicle (100 L 0.9% saline). To establish the most
effective dose of PDRN under these experimental condi-
tions, we performed a dose-response experiment using 42
rats that were randomized as follows: sham HLI  vehicle
(n  7), HLI  vehicle (n  7), and HLI treated with
PDRN at 2, 4, 8 and 16mg/kg (n 7 in each experimental
group). Rats underwent laser Doppler evaluation at day 0,
7, 14, and 21 after the surgical procedure to estimate
changes in perfusion.
A total of 82 animals were then used in the experiment
done with the most effective dose. After surgery, rats were
randomly assigned to four different groups: sham HLI 
vehicle, sham HLI  PDRN, HLI  vehicle, and HLI 
PDRN. Immediately after ischemia, animals were treated
thereafter daily with the most effective dose of PDRN (8
mg/kg IP) or with its vehicle. Groups of 28 animals (7 for
each treatment) were used to evaluate laser Doppler perfu-
sion imaging, VEGF messenger RNA (mRNA), and pro-
tein at 7, 14, and 21 days.
To clarify whether PDRN activity was mediated by the
A2A receptor, three additional groups of 28 animals were
treated daily either with 8-mg/kg PDRN IP or 0.1-mg/kg
3,7-dimethyl-1-propargilxanthine (DMPX) IP (sham
HLI  DMPX, HLI  DMPX, and HLI  PDRN 
DMPX). In these last groups, we analyzed the changes in
perfusion, the time course of VEGF mRNA and protein
expression, and tissue edema. Tissue edema was evaluated
only at day 7 in the adductor longus and histologic damage
only at day 21. Evaluations of VEGF mRNA and protein
expression and the histologic analysis were performed in
the adductor magnus muscle, sectioned in two parts, one
for histology and one for molecular analysis.
Laser Doppler perfusion imaging. After anesthesia,
hair was removed from both legs using a depilatory cream.
Hind limb perfusion was measured using a PIM 1.0 laser
Doppler perfusion imager (Perimed/Periscan, Stockholm,
Sweden). Measurements were obtained over the same re-
gions of interest (leg and foot) on the day of surgery
(baseline), 10 minutes after arterial excision, and at 7, 14
and 21 days after surgery. The laser source was mounted
onto a movable rack exactly 20 cm above the rat limbs, the
laser beam (780 nm) reflecting frommoving red blood cells
in vessels was detected and processed to provide a comput-
erized color-coded photographs. The recorded images
were analyzed by the instrument’s software, and the aver-
age perfusion of the ischemic and nonischemic limb was
calculated. Low or no perfusion is displayed as dark blue,
whereas the highest perfusion interval is displayed as red.
To account for variables such as ambient light and temper-
ature, the results were expressed as the ratio of perfusion in
the left (ischemic) vs right (nonischemic) limb.
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tion of VEGF. Muscle samples were homogenized in lysis
buffer (1% Triton, 20 mM Tris/HCl [pH 8.0], 137 mM
NaCl, 10% glycerol, 5mM ethylenediaminetetraacetic acid,
1 mM phenylmethylsulfonyl fluoride, 1% aprotinin, and
15-g/mL leupeptin). Protein samples (30 g) were de-
natured in reducing buffer (62-mmol/L Tris [pH 6.8],
10% glycerol, 2% sodium dodecyl sulfate [SDS], 5% -
mercaptoethanol, and 0.003% bromophenol blue) and sep-
arated by electrophoresis on a SDS (12%) polyacrylamide
gel. The separated proteins were transferred on to a nitro-
cellulose membrane using the transfer buffer (39-mmol/L
glycine, 48 mmol/L-Tris [pH 8.3], and 20% methanol) at
200 mA for 1 hour. The membranes were stained with
Ponceau (0.005% in 1% acetic acid) to confirm equal
amounts of protein and blocked with 5% nonfat dry milk in
Tris-buffered saline (TBS)-0.1% Tween for 1 hour at room
temperature, washed three times for 10 minutes each in
TBS-0.1% Tween, and incubated with a primary phosphor-
ylated antibody for VEGF (Chemicon, Temecula, Calif) in
TBS-0.1% Tween (1:1000) overnight at 4°C. After being
washed three times for 10 minutes each in TBS-0.1% Tween,
the membranes were incubated with a specific peroxidase-
conjugated secondary antibody (1:20.000; Pierce, Chester,
UK) for 1 hour at room temperature.
The membranes were washed and analyzed by the
enhanced chemiluminescence system according to the
manufacture’s protocol (Amersham Bioscience, Amer-
sham, UK). The VEGF protein signal was quantified by
scanning densitometry using a bioimage analysis system
(Bio-Profil, Celbio, Milan, Italy). The results from each
experimental group were expressed as relative integrated
intensity compared with control measured with the same
batch. Equal loading of protein was assessed on stripped
blots by immunodetection of -actin with a rabbit
monoclonal antibody (diluted 1:500; Cell Signaling,
Danvers, Mass) and peroxidase-conjugated goat antirab-
bit immunoglobulin G (diluted 1:15000; Pierce). All
antibodies were purified by protein A and peptide-affin-
ity chromatography.
RNA extraction and real-time polymerase chain
reaction. Adductor muscles were processed for isolation
of total RNA using Trizol Reagent (Invitrogen, Milan,
Italy), and the procedure was performed according to the
protocol provided by the manufacturer. The RNA from
each sample was dissolved in 50 L of sterile RNAse-free
water, quantified spectrophotometrically, and either stored
at 80°C or used immediately for real-time polymerase
chain reaction (PCR). The concentration and purity of
RNA were estimated by calculating the ratio of absorbance
at 260 nm to absorbance at 280 nm using an ultraviolet
spectrophotometer (BioPhotometer, Eppendorf, Ham-
burg, Germany). The total RNA isolated with this protocol
had an A260/A280 ratio of 1.8:2.2.
Total RNA (5 g) from each sample was reverse tran-
scribed using the High Capacity complementary DNA
(cDNA) Archive Kit according to the manufacturer’s man-
ual (Applied Biosystem). The cDNA from each sample(5 ng) was amplified by real-time PCR with 2X TaqMan
universal PCR Mastermix (Applied Biosystem), 20X target
primer, and probe. -Actin was used as the housekeeping
gene. Each sample was analyzed in duplicates using SDS
7300 (Applied Biosystem). The results were expressed as
the n-fold difference relative to normal controls (relative
expression levels).
Measurement of malondialdehyde content. Deter-
mination of malondialdehyde (MDA) was done to estimate
the extent of lipid peroxidation in adductor muscle. The
assay was done by using a colorimetric commercial kit (lipid
peroxidation assay kit, Calbiochem-Novabiochem Corp,
San Diego, Calif). We used for our experiments the MDA-
586 method, which is specific to assay free MDA, or after a
hydrolysis step, total MDA. The assay serves to minimize
interference from other lipid peroxidation products, such as
4-hydroxyalkenals.
Determination of tissue edema. Skeletal muscle
edema was quantified in adductor longus muscles by mea-
suring tissue wet weight-dry weight ratio at day 7. Imme-
diately after harvest, tissue samples were blotted, weighed,
and placed in a drying oven at 55°C until a constant weight
was obtained. Muscle edema was quantified by measuring
the wet weight-dry weight ratio.
Histologic evaluation. The adductor magnus mus-
cles were obtained from both ischemic and nonischemic
leg, fixed in 4% buffered formaldehyde, and then embed-
ded in paraffin. The paraffin-embedded samples were sec-
tioned and stained with hematoxylin and eosin for routine
histologic studies. Slides were evaluated by three differ-
ent pathologists blinded to the treatment. The variables
examined and scored15 were presence of necrosis, tissue
edema, presence of hemorrhagia, inflammatory cell infil-
tration, and tissue architecture. A score of 0 represents
the intact muscle and a score of 5 a necrotic muscle, as
specified in the Table.
Immunohistochemistry. Paraffin-embedded tissues
from animals sacrificed at day 14 were sectioned, and antigen
retrieval was performed using 0.05M sodium citrate buffer.
Tissues were treated with primary antibody against platelet-
endothelial cell adhesion molecule 1 (PECAM-1; Santa Cruz
Biotechnology, Santa Cruz, Calif) or VEGF (Upstate
Biotech, Lake Placid, NY). Secondary antibody was pro-
vided by Innovex (Richmond, Calif), and the location of
the reaction was visualized with 3,3=-diaminobenzidine
tetrahydrochloride (Sigma, St Louis, Mo). Slides were
then mounted with coverslips. Histologic assays were all
batch processed and used quality controls. A negative
control (nonimmune serum plus detection reagent) and
positive control (ileum for CD31, breast angiosarcoma
for VEGF) was performed on each run.
The angiogenic response was determined by counting
the number of PECAM-1–positive capillaries/mm2 in at
least 10 fields per specimen (original magnification 40).
The assessor was blinded to the specimen identity.
Drugs. PDRNwas a kind gift ofMastelli Srl, Sanremo,
Italy. It was freshly prepared and dissolved in 0.9% saline
solution.
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standard deviation. Differences in skeletal muscle damage
between treatment groups were examined for significance by
Fig 1. A, Blood flow evaluated by laser Doppler at 10
(HLI) in the various treatment groups. Rats were admin
(PDRN), at 2, 4, 8, or 16 mg/kg daily, starting immedi
flow in treated rats. The blood flow of ischemic hind limb
limb. *P 
 .005 vs HLI  vehicle. B, Percentage of blo
evaluated by laser Doppler at 7, 14, and 21 days after
intraperitoneal PDRN (2, 4, 8, and 16 mg/kg daily) st
restored blood flow in treated animals. *P 
 .005 vs HL
21 after HLI in the experimental groups. The blood flo
compared with the uninjured limb. *P 
 .005 vs HLI
deviation. DMPX, 3,7-dimethyl-1-propargilxanthine.
Table. Criteria for histologic score
Score Presence of necrosis Tissue edema
0 No fiber damage Not present N
1 Localized and/or sparsely scattered
fiber destruction
Slightly present N
2 More extensive necrosis after major
connective tissue planes and
involving few muscle fascicles
Present S
3 More extensive necrosis after major
connective tissue planes and
involving numerous muscle
fascicles
Present P
4 Destruction of almost all the entire
muscle mass in the eye-field
Present P
5 Destruction of essentially the entire
muscle mass in the eye-field.
Present Pusing the 	2 test, and values of P 
 .05 were consideredsignificant. Agreement between examiners’ scorings yielded a
rank correlation coefficient of 0.93 for the entire study. For all
other data, one-way or two-way analysis of variance (when a
tes, and at 7, 14, and 21 days after hind limb ischemia
d the vehicle or intraperitoneal polydeoxyribonucleotide
after surgery. PDRN (8 and 16 mg/kg) restored blood
ressed as a relative amount compared with the uninjured
w vs animals undergoing sham operations (sham HLI)
limb ischemia. Rats were administered the vehicle or
immediately after surgery. PDRN (8 and 16 mg/kg)
ehicle. C, Blood flow evaluated by laser Doppler at day
ischemic hind limb was expressed as a relative amount
ehicle. Error bars in the panels represent the standard
esence of hemorrhagia
Inflammatory
cell infiltration Tissue architecture
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PDRN improves tissue perfusion of ischemic hind
limb. All animals recovered well from anesthesia and were
normally moving in the cage the day after surgery. As a
consequence of femoral artery excision, blood flow signifi-
cantly diminished in all the ischemic groups 10 minutes
after surgery (Fig 1, A and B). The untreated ischemic
animals showed an almost not significant increase in blood
flow evaluated 7, 14 and 21 days after surgery (Fig 1, C),
whereas a slight increase in blood flow over time was
observed in the ischemic hind limbs of animals treated with
PDRN at 2 and 4 mg/kg (Fig 1; P  .4 vs ischemic at all
time points). In contrast, a marked increase in blood flow
was noticed in ischemic limbs treated with PDRN at 8
mg/kg after 7 days and gradually over time (Fig 1; P 

.0001 at 7, 14, and 21 days). No further increase in blood
flow was observed with the 16-mg/kg dose of PDRN.
Thus for the subsequent assessment, we used the
8-mg/kg dose. The concomitant administration of
DMPX abolished the positive effects of PDRN. DMPX
alone did not modify blood flow in sham HLI or HLI
animals (Fig 1, C).
Fig 2 shows laser Doppler perfusion images of tissue
perfusion of the several study groups at 10 minutes, and 7,
14 and 21 days after surgical procedures. The fall in perfu-
sion, shown by the blue color, was apparent 10 minutes
after artery excision, with no differences between the isch-
emic groups. In the ischemic group, the laser Doppler
LHelcihev+ILHmahS
B
C
D
Sham HLI + PDRN 8mg
A
Fig 2. Laser Doppler images at (RowA) 10minutes, an
limb ischemia (HLI). Polydeoxyribonucleotide (PDRN)
3,7-dimethyl-1-propargilxanthine.perfusion images show a partial recovery after 21 days,whereas the ischemic animals treated with PDRN had a
complete recovery starting from day 7, as highlighted by
the red color (Fig 2). A moderate ischemia occurred also in
the contralateral hind limb of untreated ischemic animals,
as observed in laser Doppler perfusion images shown in
Fig 3. PDRN treatment was also able to abate the ischemic
damage in the contralateral limb. PDRN did not affect
blood flow in sham HLI animals (Fig 2). The concomitant
administration of DMPX abolished the positive effects of
PDRN in HLI rats, but DMPX alone did not affect blood
flow in sham HLI and HLI animals (Fig 2). Moreover,
blood flow was still increased in PDRN-treated HLI ani-
mals 1 month after surgical procedures (data not shown).
PDRN stimulates VEGF expression in ischemic
hind limb. We examined the expression of VEGF mRNA
and protein in adductor muscles by real-time PCR and
Western blotting (Fig 3). In the sham HLI rats, VEGF was
not detectable throughout the experiment. In HLI animals
treated with vehicle, VEGF mRNA and protein slightly
increased. In contrast, treatment with PDRN signifi-
cantly enhanced the amount of VEGF mRNA and pro-
tein in HLI rats at day 7, with a further increase at day
14. PDRN administration did not modify VEGF expres-
sion in sham HLI rats (Fig 3). The concomitant admin-
istration of DMPX abolished the positive effects of
PDRN on VEGF mRNA and protein synthesis. DMPX
alone did not modify VEGF expression in sham HLI and
gm8NRDP+ILHelcih HLI + PDRN 8mg + DMPX
RowB) 7, (RowC) 14, and (RowD) 21 days after hind
mg/kg, restored blood flow in treated animals. DMPX,ev+I
d at (
, at 8HLI animals (Fig 3).
ethy
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in ischemic hind limb. As a consequence of critical limb
ischemia, untreated rats developed a marked edema (5.8
0.6; P 
 .0001 vs sham, Fig 4, E) 7 days after surgery.
PDRN treatment significantly reduced the degree of tissue
edema detected in adductor muscles 7 days after surgical
procedures (3.5 0.8; P .0001 vs HLI vehicle; Fig 4,
E). The concomitant administration of DMPX reversed the
effects of PDRN in HLI animals. DMPX alone did not
modify tissue edema in shamHLI and HLI animals (results
not shown). PDRN did not modify the wet weight-dry
weight ratio in sham HLI rats (Fig 4, E).
Oxidative stress was measured by the means of MDA
levels in both the ischemic (left) and contralateral (right)
adductor muscles as a consequence of ischemia: After 7
days, MDA levels increased dramatically in HLI animals
(left limb, 7.1 2 nmol/mg of tissue; right limb, 3.5 0.8
nmol/mg of tissue; P 
 .01 vs sham HLI). PDRN daily
administration blunted this increase in both limbs (left,
2.5 0.7 nmol/mg of tissue; right, 1.8 0.5 nmol/mg of
tissue; P
 .05 vs HLI). The concomitant administration of
Fig 3. A,Western blots for vascular endothelial growth
(HLI).Upper panel, Representative autoradiography hi
representing the mean  SD of seven experiments. *P
messenger RNA for VEGF at 7, 14, and 21 days after HL
.005 and #P 
 .0001 vs HLI  vehicle. DMPX, 3,7-dimDMPX reversed the beneficial effect of PDRN.Histologic evaluation. A complete histologic exami-
nation was performed after 21 days. The histologic pictures
and the histologic score shown in Fig 4 (A-D) clearly
demonstrate a marked edema with cellular infiltration, pri-
marily macrophages and necrotic degeneration of muscle
fibers of the adductor in HLI animals (Fig 4, B), when
compared with the sham HLI animals (Fig 4, A). Animals
treated with PDRN showed a marked decrease in edema,
with no sign of cellular infiltration ormuscular necrosis (Fig
4, C). The concomitant administration of DMPX reversed
the effects of PDRN in HLI animals (results not shown).
DMPX alone did not modify the histologic pattern in sham
HLI and HLI animals (results not shown). PDRN did not
modify histology in sham HLI rats (results not shown).
Moreover, the immunostaining for PECAM-1 (Fig 5,
A and B), performed to identify new capillaries between
fibers, revealed a sustained angiogenesis in PDRN-treated
HLI animals. When compared withHLI vehicle animals,
DMPX administration reversed the angiogenic effect of
PDRN (Fig 5, C). In fact, angiogenesis in PDRN-treated
animals was sustained by an increased VEGF production by
r (VEGF) at 7, 14, and 21 days after hind limb ischemia
hting VEGF expression. Lower panel, quantitative data
5 and #P 
 .0001 vs HLI  vehicle. B, Expression of
rs represent the mean SD of seven experiments. *P

l-1-propargilxanthine; PDRN polydeoxyribonucleotide.facto
ghlig

 .00
I. Bathe macrophages present in the site of ischemia, as demon-
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and confirmed by immunostaining (Fig 5, D and E).
DISCUSSION
The clinical consequences of PAOD include pain on
walking, pain at rest, and loss of tissue integrity in the distal
ischemic limbs. Although development of beneficial drugs
and intervention devices have contributed to the treatment
of this disease, critical limb ischemia is estimated to develop
in 500 to 1,000 individuals per million each year.16 Because
angiogenic growth factors can stimulate the development
of collateral arteries, a concept called “therapeutic angio-
genesis” is now being evaluated in various clinical fields.
Recent progress in molecular biology has led to the
development of gene therapy as a new strategy to treat a
variety of cardiovascular diseases using angiogenic growth
factors such as VEGF.17 Therapeutic angiogenesis using
angiogenic growth factors, particularly VEGF, is expected
to be a new treatment for patients with severe PAOD. The
most used approaches have been based on VEGF local
delivery but failed to meet the primary objective of signifi-
cant amputation reduction.18 As summarized in a recent
review,17 other treatments have been studied in patients
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muscles of both legs at day 7 after ischemia. PDRN dim
HLI. DMPX, 3,7-dimethyl-1-propargilxanthine.with critical limb ischemia, such as the delivery of cytokinegrowth factor, but larger clinical studies have failed to
achieve concrete results.
An increased understanding of the complex mecha-
nisms involved in angiogenesis has resulted in gene
therapy19 and cell therapy20 being moved to the forefront
of therapeutic angiogenesis, but we are still far from the
identification of a definitive treatment. To date, no other
drug treatment has been demonstrated efficacious in stim-
ulating angiogenesis in the ischemic limb; furthermore, it
has been shown that adenosine receptor stimulation can
induce the expression of VEGF inmany types of cells,21 and
this may be achieved by stimulating the A2A or A2B recep-
tor, or both, following the signaling pathways activated by
hypoxia.21,22 In addition. A2A receptors are expressed on
different cell types, especially under ischemic condi-
tions.23-27
These observations, together with our previous find-
ings on the ability of PDRN to induce VEGF expression
during altered healing conditions such as diabetes11 and
burn injury,12 acting through the A2A receptor, led us to
hypothesize that PDRN could be also efficacious in stimu-
lating VEGF and revascularization in the ischemic limb.
C
7)
PX
Malondialdehyde (day 7)
0
5
10
nm
ol
/m
g 
of
 ti
ss
ue
HLI + PDRN (right limb)
HLI+PDRN+DMPX (left limb)
HLI+PDRN+DMPX (right  limb)
HLI + PDRN (left limb)
HLI (right limb)
HLI (left limb)
sham HLI (right limb)
sham HLI (left limb)
#
#
F
limb ischemia (HLI) at day 21 (original magnification
l muscular architecture. B,HLI animal adductor muscle
sis. C, Adductor muscle from HLI rats treated with
g daily, showing reduced edema and cellular infiltration
score obtained from seven animals. *P
 .005 vs HLI
ay 7 after ischemia. PDRN (8 mg/kg) diminished the
hicle. F, Malondialdehyde levels evaluated in adductor
ed the degree of edema in treated animals. #P 
 .05 vs (day 
*
 + DM
hind
orma
necro
g/k
logic
s at d
 ve
inishIndeed, in this study we demonstrated the beneficial role of
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in an experimental model of PAOD.
Femoral artery ligation and excision provoked an im-
mediate impairment in perfusion, as revealed by laser
Doppler flowmetry that persisted after 21 days after the
surgical procedures. The inflammatory reaction conse-
quent to the observed muscular damage is also responsible
for the marked edema found in the ischemic limbs. The
administration of PDRN, likely through the stimulation of
the adenosine A2A receptor, induced VEGF synthesis and
release with a consequent neovascularization, as demon-
strated by the incremented perfusion and number of capil-
laries in the ischemic limb as well as by the ameliorated
histologic pattern. Indeed, the concomitant administration
of DMPX, a potent and selective adenosine A2A receptor
antagonist,28 abolished the effects of PDRN on blood flow
restoration and VEGF production, as we previously ob-
served in conditions of altered skin flow.11,12
Ischemia causes also a defective perfusion of the con-
tralateral limb as a consequence of the augmented oxidative
stress. In fact, when ischemia occurs in a system that is
strictly connected with another one, as is the case of limbs,
is not surprising that a compensatory mechanism is acti-
vated in the contralateral apparatus that may be stressed and
BA
D E
Fig 5. Immunohistologic evaluation of adductor mu
magnification 40). A, Adductor muscle from HLI anim
(PECAM-1). Arrowhead shows very slight positive cap
animal treated with polydeoxyribonucleotide (PDRN; 8
capillaries between muscle fibers. *P 
 .005 vs HLI 
presented; each bar is the mean of seven animals. *P 
 .0
stained with vascular endothelial growth factor (VEG
E, Adductor muscle from HLI animal treated with PDR
cells between muscle fibers.in turn results ischemia even if in a lower extent. Theischemia we showed in the contralateral limb was present in
all the HLI animals and we strongly believe that this cannot
confound the results of PDRN, but the amelioration seen
also in the contralateral limb may be a further proof of
PDRN efficacy, as confirmed by the reduced MDA levels
observed in both the ischemic and the contralateral limb.
Besides the local injury that occurred within the muscle
subjected to ischemia, the contralateral muscles also sus-
tained remote injury, which was confirmed in our experi-
mental model by a reduction in blood flow in the contralat-
eral limb, and PDRN succeeded also in ameliorating this
alteration.
These data collectively suggest that PDRN may fa-
vorably alter the longitudinal profile of critical limb
ischemia towards revascularization, rather than simply
sustain the process, and may have important clinical
relevance for the safe and efficacious profile of this drug.
PDRN has no antigenic properties since it consists of
low-molecular-weight DNA fractions that can be defined
as deoxyribonucleotide linear polymers. It is obtained by
extraction from trout sperm and is then purified and
sterilized to obtain 95% of DNA without pharmaco-
logically active proteins and peptides.
Moreover, in previous unpublished observations,
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le. C, The mean  SD number of capillaries/mm2 are
s HLI  vehicle. D, Adductor muscle from HLI animal
rrowheads show positive cells between muscle fibers.
mg/kg) stained with VEGF. Arrowheads show positivescles
al st
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vehic
05 v
F). A
N (8PDRN did not show any toxicity in primary cultures of rat
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Furthermore, acute and chronic toxicity studies have been
performed in mice and rats, and systemic administration of
PDRN caused neither death, nor toxic effects on liver,
lungs, brain, skeletal muscle, and heart evaluated macro-
scopically and by means of histologic analysis.
Because PDRN is approved in Italy for both parenteral
and topical use (Registration Dossier, Ministry of Health),
we hypothesized that in the future it might replace other
systemic treatments that are usually difficult to manage and
can be responsible for serious adverse effects; on the other
hand, further studies are still needed to fully understand the
benefits and limits of this compound.
CONCLUSION
This study used a novel approach to increase endoge-
nous expression of vascular endothelial growth factor in a
preclinical model of PAOD, where the capacity to induce
therapeutic angiogenesis is known to be very difficult. To
date, this is at least one of themost relevant studies showing
beneficial effects of a drug with a high safety profile in
critical limb ischemia. This approach will serve as a valuable
link to advance this and related approaches, toward human
investigation.
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technical support and to Dr. Margherita Calò for her
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supplying the PDRN.
AUTHOR CONTRIBUTIONS
Conception and design: AB, FS
Analysis and interpretation: AB, FP
Data collection: FP, LM, AM
Writing the article: AB, FS
Critical revision of the article: AB, FS
Final approval of the article: AB, FS
Statistical analysis: AB, FP
Obtained funding: FS, DA
Overall responsibility: FS
AB and FP contributed equally to this work
REFERENCES
1. Dormandy J, Heeck L, Vig S. The natural history of claudication: risk to
life and limb. Semin Vasc Surg 1999;12:123-37.
2. Gillum RF. Peripheral arterial occlusive disease of the extremities in the
United States: hospitalization and mortality. Am Heart J 1990;120:
1414-8.
3. Garcia LA. Epidemiology and pathophysiology of lower extremity
peripheral arterial disease. J Endovasc Ther 2006;13(suppl 2):II3-9.
4. Rissanen TT, Vajanto I, Yla-Herttuala S. Gene therapy for therapeutic
angiogenesis in critically ischaemic lower limb–on the way to the clinic.
Eur J Clin Invest 2001;31:651-66.
5. Ji JW, Mac Gabhann F, Popel AS. Skeletal Muscle VEGF gradients in
peripheral arterial disease: simulations of rest and exercise. Am J Physiol
Heart Circ Physiol 2007;293:H3740-9.
6. Waters RE, Terjung RL, Peters KG, Annex BH. Preclinical models of
human peripheral arterial occlusive disease: implications for investiga-
tion of therapeutic agents. J Appl Physiol 2004;97:773-80.
7. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki
K, et al. Therapeutic angiogenesis induced by human hepatocytegrowth factor gene in rat diabetic hind limb ischemia model: molecular
mechanisms of delayed angiogenesis in diabetes. Circulation
2001;104:2344-50.
8. Montesinos MC, Gadangi P, Longaker M, Sung J, Levine J, Nilsen D,
et al. Wound healing is accelerated by agonists of adenosine A2 (G alpha
s- linked) receptors. J Exp Med 1997;186:1615-20.
9. Khoa ND, Montesinos CM, Williams AJ, Kelly M, Cronstein BN. Th1
cytokines regulate adenosine receptors and their downstream signalling
elements in human microvascular endothelial cells. J Immunol 2003;
171:3991-8.
10. Leibovich S, Chen JF, Belem P, Elson G, Rosania A, RamanathanM, et
al. Synergistic up-regulation of vascular endothelial growth factor
(VEGF) expression in murine macrophages by adenosine A2A receptor
agonists and endotoxin. Am J Pathol 2002;160:2231-44.
11. Galeano M, Bitto A, Altavilla D, Minutoli L, Polito F, Calo’ M, et al.
Polydeoxyribonucleotide stimulates angiogenesis and wound healing in
the genetically diabetic mouse. Wound Rep Reg 2008;16:208-17.
12. Bitto A, Galeano M, Squadrito F, Minutoli L, Polito F, Dye JF, et al.
Polydeoxyribonucleotide improves angiogenesis and wound healing in
experimental thermal injury. Crit Care Med 2008;36:1594-602.
13. Bianchini P, Tellini N, Morani AM, Follano MG. Pharmacological data
on polydeoxyribonucleotide of human placenta. Int J Tissue Reac
1981;3:151-4.
14. Chalothorn D, Zhang H, Clayton JA, Thomas SA, Faber JE. Cat-
echolamines augment collateral vessel growth and angiogenesis in hind-
limb ischemia. Am J Physiol Heart Circ Physiol 2005;289:H947-59.
15. Benoit PW, Yagiela JA, Fort NF. Pharmacological correlation between
local anesthetic-induced myotoxicity and disturbances of intracellular
calcium distribution. Toxicol Appl Pharmacol 1980;52:187-98.
16. Novo S, Coppola G, Milio G. Critical limb ischemia: definition and
natural history. Curr Drug Targets Cardiovasc Haematol Disord 2004;
4:219-25.
17. Jones WS, Annex BH. Growth factors for therapeutic angiogenesis in
peripheral arterial disease. Curr Opin Cardiol 2007;22:458-63.
18. Kusumanto YH, vanWeel V, Mulder NH, Smit AJ, van den Dungen JJ,
Hooymans JM, et al. Treatment with intramuscular vascular endothelial
growth factor gene compared with placebo for patients with diabetes
mellitus and critical limb ischemia: a double-blind randomized trial.
Hum Gene Ther 2006;17:683-91.
19. Makino H, Ogihara T, Morishita R. Gene therapy for peripheral arterial
diseases. Nippon Rinsho 2005;63:491-7.
20. Tateishi-Yuyama E, Matsubara H, Murohara T, Ikeda U, Shintani S,
Masaki H, et al. Therapeutic angiogenesis for patients with limb isch-
aemia by autologous transplantation of bone-marrow cells: a pilot study
and a randomised controlled trial. Lancet 2002;360:427-35.
21. Adair TH. Growth regulation of the vascular system: an emerging role
for adenosine. Am J Physiol Regul Integr Comp Physiol 2005;289:
R283-96.
22. Feoktistov I, Ryzhov S, Zhong H, Goldstein AE, Matafonov A, Zeng
D, et al. Hypoxia modulates adenosine receptors in human endothelial
and smooth muscle cells toward an A2B angiogenic phenotype. Hyper-
tension 2004;44:649-54.
23. Linden J. Molecular approach to adenosine receptors: receptor-
mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxi-
col 2001;41:775-87.
24. Fredholm BB. Adenosine, an endogenous distress signal, modulates
tissue damage and repair. Cell Death Differ 2007;14:1315-23.
25. Lukashev D, Ohta A, SitkovskyM. Targeting hypoxia-A(2A) adenosine
receptor-mediated mechanisms of tissue protection. Drug Discov To-
day 2004;9:403-9.
26. Fredholm BB. Adenosine receptors as targets for drug development.
Drug News Perspect 2003;16:283-9.
27. O’Regan M. Adenosine and the regulation of cerebral blood flow.
Neurol Res 2005;27:175-81.
28. Seale TW, Abla KA, Shamim MT, Carney JM, Daly JW. 3,7-Dimethyl-
1-propargylxanthine: a potent and selective in vivo antagonist of aden-
osine analogs. Life Sci 1988;43:1671-84.Submitted Mar 17, 2008; accepted Jun 10, 2008.
